In recent years the discovery of cancer biomarkers has become a major focus of cancer research. The widespread use of prostate-specific antigen in prostate cancer screening has motivated researchers to identify suitable markers for screening different types of cancer. Biomarkers are also useful for diagnosis, monitoring disease progression, and predicting disease recurrence.
For More Insights, Grab PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=479
With the advent of new & improved genomic & proteomic technologies such as DNA & tissue microarray, two-dimensional gel electrophoresis, mass spectrometry & protein assays coupled with advanced bioinformatic tools, it is possible to develop biomarkers that are able to reliably & accurately predict outcomes during cancer management & treatment.
The future of clinical cancer management belongs to the prognostic & predictive biomarkers of cancer. These markers are of utmost importance as they will be used to make clinical decisions that will eventually save lives. In the future, biomarkers will guide decision-making during cancer management. Biomarkers that correctly predict outcomes in a specific disease & allow physicians & patients to make informed treatment decisions need to be developed.